NCT02982915View on ClinicalTrials.gov

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2022

Conditions
Aging Frailty
Interventions
BIOLOGICAL

Longeveron Mesenchymal Stem Cells (LMSCs)

Intravenously delivered

BIOLOGICAL

Fluzone High Dose Vaccine

Intramuscular injection

Trial Locations (6)

20850

Optimal Research LLC, Rockville

21224

Johns Hopkins University, Baltimore

33134

Clinical Research of South Florida, Coral Gables

33136

University of Miami, Miami

33176

Vista Health Research, Miami

33912

Clinical Physiology Associates, Fort Myers

Sponsors

Lead Sponsor

Longeveron Inc.
All Listed Sponsors
lead

Longeveron Inc.

INDUSTRY

NCT02982915 - Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty | Biotech Hunter | Biotech Hunter